344 related articles for article (PubMed ID: 32638567)
1. Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis.
Vultaggio A; Nencini F; Bormioli S; Vivarelli E; Dies L; Rossi O; Parronchi P; Maggi E; Matucci A
Allergy Asthma Immunol Res; 2020 Sep; 12(5):885-893. PubMed ID: 32638567
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Low-Dose Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Real-Life Experience.
Özdel Öztürk B; Yavuz Z; Aydın Ö; Mungan D; Sin BA; Demirel YS; Bavbek S
Int Arch Allergy Immunol; 2022; 183(12):1281-1290. PubMed ID: 36126640
[TBL] [Abstract][Full Text] [Related]
4. Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis (EGPA) in Japan: 48-week interim analysis of the MARS study.
Ishii T; Kunishige H; Kobayashi T; Hayashi E; Komatsubara M; Ishii T; Alfonso-Cristancho R; Tamaoki J; Howarth P
Mod Rheumatol; 2023 Dec; ():. PubMed ID: 38100679
[TBL] [Abstract][Full Text] [Related]
5. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan.
Yamane T; Hashiramoto A
Arthritis Res Ther; 2023 Jun; 25(1):110. PubMed ID: 37365612
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW; Akuthota P; Cid MC; Gleich GJ; Jayne D; Khoury P; Langford CA; Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME
J Allergy Clin Immunol; 2019 Jun; 143(6):2170-2177. PubMed ID: 30578883
[TBL] [Abstract][Full Text] [Related]
7. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy.
Faverio P; Bonaiti G; Bini F; Vaghi A; Pesci A
Ther Clin Risk Manag; 2018; 14():2385-2396. PubMed ID: 30573961
[TBL] [Abstract][Full Text] [Related]
8. Sinonasal and respiratory outcomes of eosinophilic granulomatosis with polyangiitis patients receiving 100 mg mepolizumab in real-life clinical practice: 1-year follow up study.
Can Bostan O; Duran E; Tuncay G; Cihanbeylerden M; Karadag O; Damadoglu E; Karakaya G; Kalyoncu AF
J Asthma; 2023 May; 60(5):931-937. PubMed ID: 35912568
[No Abstract] [Full Text] [Related]
9. [Anti-IL-5 in severe asthma associated with eosinophilic granulomatosis with polyangiitis. Real-life study].
Akdime F; Habib S; Regard L; Terrier B; Cohen P; Mouthon L; Guillevin L; Burgel PR; Honore I; Puéchal X; Roche N
Rev Mal Respir; 2023; 40(9-10):732-742. PubMed ID: 37923651
[TBL] [Abstract][Full Text] [Related]
10. Factors Affecting the Ability to Discontinue Oral Corticosteroid Use in Patients with EGPA Treated with Anti-Interleukin-5 Therapy.
Matsuno O
Int Arch Allergy Immunol; 2024; 185(2):116-123. PubMed ID: 37906985
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and Disease Burden of Patients With Eosinophilic Granulomatosis With Polyangiitis Initiating Mepolizumab in the United States.
Silver J; Deb A; Packnett E; McMorrow D; Morrow C; Bogart M
J Clin Rheumatol; 2023 Dec; 29(8):381-387. PubMed ID: 37779234
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis.
Desaintjean C; Ahmad K; Traclet J; Gerfaud-Valentin M; Durel CA; Glerant JC; Hot A; Lestelle F; Mainbourg S; Nasser M; Seve P; Turquier S; Devouassoux G; Cottin V
Front Med (Lausanne); 2024; 11():1341310. PubMed ID: 38585151
[TBL] [Abstract][Full Text] [Related]
13. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis.
Ríos-Garcés R; Prieto-González S; Hernández-Rodríguez J; Arismendi E; Alobid I; Penatti AE; Cid MC; Espígol-Frigolé G
Eur J Intern Med; 2022 Jan; 95():61-66. PubMed ID: 34535374
[TBL] [Abstract][Full Text] [Related]
14. Clinical Features of Patients with Active Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.
Tsurikisawa N; Oshikata C; Watanabe M; Fukuda N; Yamaguchi T; Kiyohara H; Kaneko T
Int Arch Allergy Immunol; 2021; 182(8):744-756. PubMed ID: 33887721
[TBL] [Abstract][Full Text] [Related]
15. Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series.
Detoraki A; Tremante E; Poto R; Morelli E; Quaremba G; Granata F; Romano A; Mormile I; Rossi FW; de Paulis A; Spadaro G
Respir Res; 2021 Jun; 22(1):185. PubMed ID: 34162391
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?
Vergles M; Matković Z; Lalić K; Trkanjec JT; Tudorić N
J Asthma; 2021 Dec; 58(12):1675-1679. PubMed ID: 32962455
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis.
Nanzer AM; Maynard-Paquette AC; Alam V; Green L; Thomson L; Lam J; Fernandes M; Roxas C; d'Ancona G; Hearn A; Gates J; Agarwal S; Kent BD; Fernando M; D'Cruz DP; Hopkins C; Ismail TF; Dhariwal J; Jackson DJ
J Allergy Clin Immunol Pract; 2024 Mar; 12(3):724-732. PubMed ID: 38211889
[TBL] [Abstract][Full Text] [Related]
18. Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis.
Mümmler C; Mertsch P; Barnikel M; Haubner F; Schönermarck U; Grabmaier U; Schulze-Koops H; Behr J; Kneidinger N; Milger K
J Asthma Allergy; 2024; 17():557-572. PubMed ID: 38860030
[TBL] [Abstract][Full Text] [Related]
19. Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics.
Jayne DRW; Terrier B; Hellmich B; Khoury P; Baylis L; Bentley JH; Steinfeld J; Yancey SW; Kwon N; Wechsler ME; Akuthota P
ERJ Open Res; 2024 Jan; 10(1):. PubMed ID: 38196889
[TBL] [Abstract][Full Text] [Related]
20. Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.
Bettiol A; Urban ML; Dagna L; Cottin V; Franceschini F; Del Giacco S; Schiavon F; Neumann T; Lopalco G; Novikov P; Baldini C; Lombardi C; Berti A; Alberici F; Folci M; Negrini S; Sinico RA; Quartuccio L; Lunardi C; Parronchi P; Moosig F; Espígol-Frigolé G; Schroeder J; Kernder AL; Monti S; Silvagni E; Crimi C; Cinetto F; Fraticelli P; Roccatello D; Vacca A; Mohammad AJ; Hellmich B; Samson M; Bargagli E; Cohen Tervaert JW; Ribi C; Fiori D; Bello F; Fagni F; Moroni L; Ramirez GA; Nasser M; Marvisi C; Toniati P; Firinu D; Padoan R; Egan A; Seeliger B; Iannone F; Salvarani C; Jayne D; Prisco D; Vaglio A; Emmi G;
Arthritis Rheumatol; 2022 Feb; 74(2):295-306. PubMed ID: 34347947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
